US Edition
News from curetoday.com
We’ve assigned a media bias rating of unknown to curetoday.com. You can read more about our methodology here.
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top curetoday.com News
CancerDEAR MISS MANNERS: Three years ago, I was diagnosed with cancer. I was extremely fortunate: My tumor was removed and I did not require radiation or chemo. I have my screenings yearly and all has been well. Am I a “cancer survivor”? I never want to take anything away from someone who had a much more difficult battle than I did. I don’t want to use the term incorrectly.See the Story
Miss Manners: Yes, I survived cancer, but I feel awkward about the phrase ‘cancer survivor’
75% Center coverage: 4 sources
Cancer · United StatesThe U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (combined positive score of at least 1), as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent…See the Story
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Merck & Co (NYSE:MRK)
100% Center coverage: 2 sources
Next-Generation TKI Approved for Advanced ROS1-Positive Lung Cancer
100% Center coverage: 2 sources
Sasanlimab Plus BCG in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer: the Randomized Phase 3 CREST Trial
100% Center coverage: 2 sources
